|
|
 | | | |
- close
- close
- close
- close
Rigel Pharmaceuticals (RIGL) |
StreetInsider.com
May 22
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rigel+Pharma+%28RIGL%29+Advances+R348+to+Phase+2/8360786.html for the full story.
StreetInsider.com
May 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Rigel+Pharmaceuticals%2C+Inc.+%28RIGL%29+Tops+Q1+Loss+Views/8310654.html for the full story.
StreetInsider.com
Apr 5
Comment
Rigel Pharmaceuticals (Nasdaq: RIGL) 35.5% LOWER; AstraZeneca announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for...
Benzinga
Apr 5
Comment
Rigel Pharmaceuticals (NASDAQ: RIGL) shares dropped 34.01% to $4.97 after the company announced top-line results of OSKIRA-1.
Radware Ltd. (NASDAQ: RDWR) shares lost 20.20% to $29.99 after the Israeli technology company lowered its Q1 earnings...
Benzinga
Apr 5
Comment
In a report published Friday, BMO Capital Markets analyst Jim Birchenough downgraded the rating on Rigel Pharmaceuticals (NASDAQ: RIGL) from Outperform to Market Perform, and lowered the price target from $17.00 to $8.00.
In the report,...
Wall Street Journal
Apr 5
Comment
Among the companies with shares actively trading in Friday's session are F5 Networks, Rigel Pharmaceuticals and Radware.
TheStreet.com
Apr 5
Comment
LONDON (TheStreet) -- An experimental rheumatoid arthritis pill from AstraZeneca and Rigel produced mixed results in a late-stage clinical trial, raising additional questions about the drug's future.
In the study known as OSKIRA-1, two...
Benzinga
Mar 5
Comment
In a report published Tuesday, JP Morgan maintained an Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and maintained its $10 price target.
JP Morgan reported that, “Our recommendation is primarily based on the potential for RIGL's...
StreetInsider.com
Mar 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Rigel+Pharmaceuticals%2C+Inc.+%28RIGL%29+Narrows+Q4+Loss+to+30cShare/8155284.html for the full story.
Benzinga
Dec 14
Comment
Stifel Nicolaus reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but reduced its price target from $13 to $11.
Stifel Nicolaus commented, "Rigel's development/collaboration partner AstraZeneca provided top-line results from...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
